Novoprotein Scientific Past Earnings Performance
Past criteria checks 0/6
Novoprotein Scientific's earnings have been declining at an average annual rate of -15.1%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been declining at an average rate of 38% per year.
Key information
-15.1%
Earnings growth rate
-93.0%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | -38.0% |
| Return on equity | -0.04% |
| Net Margin | -0.7% |
| Next Earnings Update | 30 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Novoprotein Scientific makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 136 | -1 | 87 | 45 |
| 31 Dec 23 | 153 | 13 | 86 | 45 |
| 30 Sep 23 | 163 | 16 | 98 | 50 |
| 30 Jun 23 | 173 | 32 | 87 | 48 |
| 31 Mar 23 | 220 | 62 | 88 | 42 |
| 31 Dec 22 | 265 | 91 | 84 | 41 |
| 30 Sep 22 | 277 | 111 | 70 | 38 |
| 30 Jun 22 | 377 | 167 | 86 | 40 |
| 31 Mar 22 | 364 | 162 | 78 | 38 |
| 31 Dec 21 | 342 | 149 | 73 | 34 |
| 31 Dec 20 | 180 | 83 | 41 | 15 |
| 31 Dec 19 | 36 | -8 | 22 | 10 |
| 31 Dec 18 | 26 | -12 | 19 | 8 |
Quality Earnings: 688137 is currently unprofitable.
Growing Profit Margin: 688137 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688137 is unprofitable, and losses have increased over the past 5 years at a rate of 15.1% per year.
Accelerating Growth: Unable to compare 688137's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688137 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: 688137 has a negative Return on Equity (-0.042%), as it is currently unprofitable.